Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (209K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (57)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Miller, V. M.
Right arrow Articles by Paulson, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, V. M.
Right arrow Articles by Paulson, H. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published online 30 January 2004

Nucleic Acids Research, 2004, Vol. 32, No. 2 661-668
© 2004 Oxford University Press

Targeting Alzheimer’s disease genes with RNA interference: an efficient strategy for silencing mutant alleles

Victor M. Miller1,2, Cynthia M. Gouvion1, Beverly L. Davidson1,2,3,4 and Henry L. Paulson*,1,2

1 Department of Neurology, 2 Graduate Program in Genetics, 3 Departments of Internal Medicine and 4 Physiology and Biophysics, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA 52242, USA

*To whom correspondence should be addressed at Department of Neurology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, 2007 RCP, Iowa City, IA 52242, USA. Tel: +1 319 335 8696; Fax: +1 319 335 7173; Email: henry-paulson{at}uiowa.edu

Tau and amyloid precursor protein (APP) are key proteins in the pathogenesis of sporadic and inherited Alzheimer’s disease. Thus, developing ways to inhibit production of these proteins is of great research and therapeutic interest. The selective silencing of mutant alleles, moreover, represents an attractive strategy for treating inherited dementias and other dominantly inherited disorders. Here, using tau and APP as model targets, we describe an efficient method for producing small interfering RNA (siRNA) against essentially any targeted region of a gene. We then use this approach to develop siRNAs that display optimal allele-specific silencing against a well-characterized tau mutation (V337M) and the most widely studied APP mutation (APPsw). The allele-specific RNA duplexes identified by this method then served as templates for constructing short hairpin RNA (shRNA) plasmids that successfully silenced mutant tau or APP alleles. These plasmids should prove useful in experimental and therapeutic studies of Alzheimer’s disease. Our results suggest guiding principles for the production of allele-specific siRNA, and the general method described here should facilitate the production of gene-specific siRNAs.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
A. Jedidi, C. Marty, C. Oligo, L. Jeanson-Leh, J.-A. Ribeil, N. Casadevall, A. Galy, W. Vainchenker, and J.-L. Villeval
Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines
Blood, August 27, 2009; 114(9): 1842 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. S. Weinberg and M. J.A. Wood
Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics
Hum. Mol. Genet., April 15, 2009; 18(R1): R27 - R39.
[Abstract] [Full Text] [PDF]

Home page
 Brief Funct Genomic ProteomicHome page
A. Jagannath and M. Wood
RNA interference based gene therapy for neurological disease
Brief Funct Genomic Proteomic, May 3, 2007; (2007) elm005v1.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
H. Paulson
RNA interference as potential therapy for neurodegenerative disease: Applications to inclusion-body myositis?
Neurology, January 24, 2006; 66(1_suppl_1): S114 - S117.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. E. Lovett-Racke, P. D. Cravens, A. R. Gocke, M. K. Racke, and O. Stuve
Therapeutic Potential of Small Interfering RNA for Central Nervous System Diseases
Arch Neurol, December 1, 2005; 62(12): 1810 - 1813.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.